What one share of BioMarin Pharmaceutical holds
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline.
BioMarin Pharmaceutical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $17.37 |
|---|---|
| Profit | $0.39 |
| Capex (buildings and equipment) | $0.61 |
| Free cash flow | $3.76 |
| Cash and investments | $4.52 |
| Debt | $21.63 |
| Book value | $32.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2008 | $2.86 | $0.30 | $0.54 | −$0.63 | — | $2.80 |
| 2009 | $3.24 | −$0.00 | $0.90 | −$0.02 | — | $3.19 |
| 2010 | $2.99 | $1.73 | $0.39 | −$0.24 | — | $6.48 |
| 2011 | $3.94 | −$0.48 | $0.65 | −$0.49 | — | $6.73 |
| 2012 | $4.16 | −$0.95 | $0.37 | −$0.22 | — | $8.07 |
| 2013 | $3.98 | −$1.28 | $0.47 | −$0.91 | — | $9.35 |
| 2014 | $5.12 | −$0.92 | $0.80 | −$1.28 | — | $10.25 |
| 2015 | $5.56 | −$1.07 | $1.42 | −$2.79 | — | $14.86 |
| 2016 | $6.72 | −$3.81 | $0.89 | −$2.26 | — | $16.02 |
| 2017 | $7.53 | −$0.67 | $1.14 | −$1.19 | — | $15.97 |
| 2018 | $8.41 | −$0.44 | $0.82 | −$0.70 | — | $16.65 |
| 2019 | $9.52 | −$0.13 | $0.81 | −$0.54 | — | $17.36 |
| 2020 | $9.71 | $4.50 | $0.60 | −$0.15 | — | $22.56 |
| 2021 | $10.10 | −$0.35 | $0.52 | $1.14 | — | $23.19 |
| 2022 | $11.09 | $0.75 | $0.64 | $0.29 | — | $24.71 |
| 2023 | $12.63 | $0.88 | $0.50 | $0.33 | — | $26.25 |
| 2024 | $14.51 | $2.21 | $0.43 | $2.48 | — | $29.66 |
| 2025 | $16.32 | $1.80 | $0.52 | $3.67 | — | $31.65 |
Common questions about BioMarin Pharmaceutical
How much does one share of BioMarin Pharmaceutical earn?
Over the last 12 months, each share of BioMarin Pharmaceutical earned $0.39 of profit on $17.37 of sales, keeping about 2¢ of every $1 (profit margin).
Does BioMarin Pharmaceutical pay a dividend?
BioMarin Pharmaceutical didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is BioMarin Pharmaceutical’s book value per share?
BioMarin Pharmaceutical’s book value is $32.66 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of BioMarin Pharmaceutical have?
Each share of BioMarin Pharmaceutical has $4.52 of cash and investments and $21.63 of debt, as of June 30, 2026.
What is BioMarin Pharmaceutical’s free cash flow per share?
$3.76 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
How has BioMarin Pharmaceutical’s profit per share changed over time?
Profit per share went from $0.30 in 2008 to $1.80 in 2025, growing about 11.2% a year (adjusted for stock splits).
Has BioMarin Pharmaceutical bought back shares?
BioMarin Pharmaceutical’s share count rose about 91% from 2008 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.